Newsroom
Sorted by: Latest
-
The New York Times Company Declares Regular Quarterly Dividend
NEW YORK--(BUSINESS WIRE)--The New York Times Company’s Board of Directors today declared a regular quarterly dividend of $0.23 per share on the Company’s Class A and Class B common stock. The dividend is payable on July 23, 2026, to shareholders of record as of the close of business on July 8, 2026. The New York Times Company (NYSE: NYT) is a trusted source of quality, independent journalism whose mission is to seek the truth and help people understand the world. With more than 13 million subs...
-
BeOne Medicines的基礎血液學產品線在EHA 2026上引領B細胞癌症創新新時代
加州聖卡洛斯--(BUSINESS WIRE)--(美國商業資訊)-- 全球性腫瘤公司BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235)今日在瑞典斯德哥爾摩舉行的2026年歐洲血液學協會(EHA)大會上公布了其基礎血液學產品線的最新資料。潛在同類最優的布魯頓酪氨酸激酶(BTK)降解劑tacabrutideg (BGB-16673)的更新結果顯示,其在經過預治療的復發/難治性(R/R)慢性淋巴性白血病/小淋巴細胞淋巴瘤(CLL/SLL)病患中展現出持久的反應,且在未接受過BTK抑制劑治療的病患中也觀察到了早期活性。此外,BRUKINSA® (zanubrutinib)與下一代BCL2抑制劑BEQALZI™ (sonrotoclax; ZS)的全口服聯合療法的結果也同步公布,該療法在多種B細胞惡性腫瘤中持續展現出快速、深度且持久的反應。 BeOne Medicines血液學醫學長Amit Agarwal, M.D.博士表示: 「BTK抑制重塑了B細胞癌症的治療格局,我們相信降解將是下一個飛躍。在本次EHA大會上,taca...
-
Riassunto: Il franchising ematologico di base di BeOne Medicines guida la prossima era dell'innovazione oncologica delle cellule B all'EHA 2026
SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), società oncologica globale, oggi ha annunciato nuovi dati provenienti dal suo franchising ematologico di base al Congresso 2026 della European Hematology Association (EHA) a Stoccolma. I risultati aggiornati di tacabrutideg (BGB-16673), un potenziale degradatore della tirosina chinasi di Bruton (BTK) best-in-class, ha dimostrato di dare risposte durature nella leucemia linfatica cronica/linfoma li...
-
ees Europe:绿色氢能机会与生产加速
德国慕尼黑和普福尔茨海姆--(BUSINESS WIRE)--(美国商业资讯)-- 向气候中性产业转型是主要经济体未来数十年的中心任务之一。欧盟承诺在2050年前实现气候中性,中国的目标是在2060年前实现气候中性。氢能是实现其制造业和能源行业转型的关键。但实际市场发展落后于这些宏伟的目标:《2025全球能源报告》显示,在当前十年之初宣布的氢能项目中,现在仅11%投入运行或得到投资决策保障。正是由于这一原因,氢能在欧洲规模最大、国际化程度最高的电池和储能系统展览ees Europe上成为各方关注的焦点。新协调的氢能对话论坛和展览将于6月23-25日在B2展厅举行,让与会者能够深入了解氢能技术的机会、技术创新、节能潜力和奠基性项目。作为该展览的补充,6月24和25日将在慕尼黑国际会议中心(ICM)举行氢能对话峰会。ees Europe是智慧欧洲(The smarter E Europe)所举办四场展览之一,届时预计将有大约2,800参展机构和超过100,000名行业参观者与会。 《2025全球能源报告》显示,2024年全球制氢大约1亿吨,其中大约99%来自化石燃料。持续的能源危机正在让世...
-
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm, Encourages Zillow Group, Inc. (Z, ZG) Shareholders To Inquire About Securities Fraud Class Action
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Zillow Group, Inc. (“Zillow” or the “Company”) (NASDAQ: Z, ZG) Class A or Class C common stock between February 11, 2025 and May 7, 2026, inclusive (the “Class Period”). Zillow investors have until August 10, 2026 to file a lead plaintiff motion.IF YOU S...
-
Samenvatting: De toonaangevende hematologie-divisie van BeOne Medicines luidt op EHA 2026 een nieuw tijdperk in voor innovatie op het gebied van B-celkanker
SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), een wereldwijd actief oncologiebedrijf, heeft vandaag tijdens het congres van de European Hematology Association (EHA) 2026 in Stockholm nieuwe gegevens uit zijn toonaangevende hematologie-portfolio bekendgemaakt. Bijgewerkte resultaten van tacabrutideg (BGB-16673), een potentieel toonaangevende Bruton's tyrosinekinase (BTK)-degrader, toonden aanhoudende responsen aan bij eerder behandelde patiënt...
-
Law Offices of Howard G. Smith Encourages Grail, Inc. (GRAL) Shareholders To Inquire About Securities Fraud Class Action
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Grail, Inc. (“Grail” or the “Company”) (NASDAQ: GRAL) common stock between May 13, 2025 and February 19, 2026, inclusive (the “Class Period”). Grail investors have until August 4, 2026 to file a lead plaintiff motion.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN GRAIL, INC. (GRAL), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE...
-
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Via Transportation, Inc. (VIA) Shareholders to Inquire About Securities Fraud Class Action
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Via Transportation, Inc. (“Via” or the “Company”) (NYSE: VIA) common stock pursuant and/or traceable to the Company’s September 2025 initial public offering (the “IPO”). Via investors have until August 10, 2026 to file a lead plaintiff motion.IF YOU SUFF...
-
Cadeler completes final turbine installation at RWE’s Sofia Offshore Wind Farm
COPENHAGEN, Denmark--(BUSINESS WIRE)--Cadeler has completed the installation of all 100 wind turbines at the 1.4 GW Sofia Offshore Wind Farm in the UK North Sea. The installation of turbine number 100 marks the completion of Cadeler's turbine installation campaign and Wind Peak's first installation project since her delivery. The 1.4 GW Sofia Offshore Wind Farm, developed by RWE and located off the UK’s north-east coast, is one of the largest single offshore wind farms in the world. Cadeler has...
-
Interim Legal AG wird in Chambers and Partners „NewLaw 2026 Guide" aufgenommen
ZÜRICH, Schweiz--(BUSINESS WIRE)--Die Interim Legal AG, ein führender Anbieter alternativer Rechtsdienstleistungen auf dem Schweizer Markt, gab heute bekannt, dass das Unternehmen von Chambers and Partners in deren „NewLaw 2026 Guide“ aufgenommen wurde. Damit ist es das erste Mal, dass ein Schweizer Anbieter flexibler juristischer Personaldienstleistungen in diesem Leitfaden aufgeführt wird. Die Rankings von Interim Legal AG werden in zwei Kategorien aufgeführt: Anbieter alternativer Rechtsdien...